Subacute cutaneous lupus erythematosus induced by nivolumab: two case reports and a literature review.
Identifieur interne : 000074 ( PubMed/Corpus ); précédent : 000073; suivant : 000075Subacute cutaneous lupus erythematosus induced by nivolumab: two case reports and a literature review.
Auteurs : Nesrine B. Zitouni ; Jean-Philippe Arnault ; Ali Dadban ; Christophe Attencourt ; Catherine C. Lok ; Guillaume ChabySource :
- Melanoma research [ 1473-5636 ] ; 2019.
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Nivolumab.
- chemically induced : Lupus Erythematosus, Cutaneous.
- pathology : Lupus Erythematosus, Cutaneous.
- chemical , pharmacology : Nivolumab.
- Adult, Aged, Female, Humans, Male.
Abstract
Nivolumab is widely used to treat several late-stage malignancies such as melanoma and non-small-cell lung cancer by inhibiting the interaction between the programmed cell death protein-1 and its ligand. By stimulating an antitumor immune response, it also leads to immune adverse events. Here. we report two cases of subacute cutaneous lupus erythematosus (SCLE) induced by nivolumab. Case 1: a 72-year-old woman with a stage IV melanoma. Two months after nivolumab discontinuation because of autoimmune hepatitis, the patient was in complete remission and pruritic nummular erythematous plaques appeared on the back and arms. Case 2: a 43-year-old man put under nivolumab for a metastatic non-small-cell lung cancer. After two cycles, an annular erythematous eruption appeared on the hands, arms, and chest. The hypothesis of SCLE was confirmed by biopsies showing lymphoid perivascular inflammatory infiltrates, with scarce C3 deposits along the basal layer of the epidermis in patient 2. Both patients tested positive for antinuclear antibodies and anti-SSA antibodies. Lesions were regressive under topical corticosteroids and hydroxychloroquine for the first patient and oral prednisone for the second patient. No systemic involvement was observed. The occurrence of SCLE 2 months after nivolumab discontinuation is evidence that the drug effect is prolonged because of the maintenance of programmed cell death protein-1 reception saturation for months. A causal relationship between SCLE and nivolumab is suggested by (i) the occurrence of SCLE after at least two cycles, (ii) the regression of lesions following treatment with corticosteroids and hydroxychloroquine, and (iii) the fact that it appeared after remission in our first patient.
DOI: 10.1097/CMR.0000000000000536
PubMed: 30489484
Links to Exploration step
pubmed:30489484Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Subacute cutaneous lupus erythematosus induced by nivolumab: two case reports and a literature review.</title>
<author><name sortKey="Zitouni, Nesrine B" sort="Zitouni, Nesrine B" uniqKey="Zitouni N" first="Nesrine B" last="Zitouni">Nesrine B. Zitouni</name>
<affiliation><nlm:affiliation>Departments of Dermatology.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Arnault, Jean Philippe" sort="Arnault, Jean Philippe" uniqKey="Arnault J" first="Jean-Philippe" last="Arnault">Jean-Philippe Arnault</name>
<affiliation><nlm:affiliation>Departments of Dermatology.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Dadban, Ali" sort="Dadban, Ali" uniqKey="Dadban A" first="Ali" last="Dadban">Ali Dadban</name>
<affiliation><nlm:affiliation>Departments of Dermatology.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Attencourt, Christophe" sort="Attencourt, Christophe" uniqKey="Attencourt C" first="Christophe" last="Attencourt">Christophe Attencourt</name>
<affiliation><nlm:affiliation>Pathology, Amiens University Hospital, Amiens, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lok, Catherine C" sort="Lok, Catherine C" uniqKey="Lok C" first="Catherine C" last="Lok">Catherine C. Lok</name>
<affiliation><nlm:affiliation>Departments of Dermatology.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Chaby, Guillaume" sort="Chaby, Guillaume" uniqKey="Chaby G" first="Guillaume" last="Chaby">Guillaume Chaby</name>
<affiliation><nlm:affiliation>Departments of Dermatology.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2019">2019</date>
<idno type="RBID">pubmed:30489484</idno>
<idno type="pmid">30489484</idno>
<idno type="doi">10.1097/CMR.0000000000000536</idno>
<idno type="wicri:Area/PubMed/Corpus">000074</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000074</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Subacute cutaneous lupus erythematosus induced by nivolumab: two case reports and a literature review.</title>
<author><name sortKey="Zitouni, Nesrine B" sort="Zitouni, Nesrine B" uniqKey="Zitouni N" first="Nesrine B" last="Zitouni">Nesrine B. Zitouni</name>
<affiliation><nlm:affiliation>Departments of Dermatology.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Arnault, Jean Philippe" sort="Arnault, Jean Philippe" uniqKey="Arnault J" first="Jean-Philippe" last="Arnault">Jean-Philippe Arnault</name>
<affiliation><nlm:affiliation>Departments of Dermatology.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Dadban, Ali" sort="Dadban, Ali" uniqKey="Dadban A" first="Ali" last="Dadban">Ali Dadban</name>
<affiliation><nlm:affiliation>Departments of Dermatology.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Attencourt, Christophe" sort="Attencourt, Christophe" uniqKey="Attencourt C" first="Christophe" last="Attencourt">Christophe Attencourt</name>
<affiliation><nlm:affiliation>Pathology, Amiens University Hospital, Amiens, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lok, Catherine C" sort="Lok, Catherine C" uniqKey="Lok C" first="Catherine C" last="Lok">Catherine C. Lok</name>
<affiliation><nlm:affiliation>Departments of Dermatology.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Chaby, Guillaume" sort="Chaby, Guillaume" uniqKey="Chaby G" first="Guillaume" last="Chaby">Guillaume Chaby</name>
<affiliation><nlm:affiliation>Departments of Dermatology.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Melanoma research</title>
<idno type="eISSN">1473-5636</idno>
<imprint><date when="2019" type="published">2019</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Female</term>
<term>Humans</term>
<term>Lupus Erythematosus, Cutaneous (chemically induced)</term>
<term>Lupus Erythematosus, Cutaneous (pathology)</term>
<term>Male</term>
<term>Nivolumab (adverse effects)</term>
<term>Nivolumab (pharmacology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Nivolumab</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Lupus Erythematosus, Cutaneous</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lupus Erythematosus, Cutaneous</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Nivolumab</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Nivolumab is widely used to treat several late-stage malignancies such as melanoma and non-small-cell lung cancer by inhibiting the interaction between the programmed cell death protein-1 and its ligand. By stimulating an antitumor immune response, it also leads to immune adverse events. Here. we report two cases of subacute cutaneous lupus erythematosus (SCLE) induced by nivolumab. Case 1: a 72-year-old woman with a stage IV melanoma. Two months after nivolumab discontinuation because of autoimmune hepatitis, the patient was in complete remission and pruritic nummular erythematous plaques appeared on the back and arms. Case 2: a 43-year-old man put under nivolumab for a metastatic non-small-cell lung cancer. After two cycles, an annular erythematous eruption appeared on the hands, arms, and chest. The hypothesis of SCLE was confirmed by biopsies showing lymphoid perivascular inflammatory infiltrates, with scarce C3 deposits along the basal layer of the epidermis in patient 2. Both patients tested positive for antinuclear antibodies and anti-SSA antibodies. Lesions were regressive under topical corticosteroids and hydroxychloroquine for the first patient and oral prednisone for the second patient. No systemic involvement was observed. The occurrence of SCLE 2 months after nivolumab discontinuation is evidence that the drug effect is prolonged because of the maintenance of programmed cell death protein-1 reception saturation for months. A causal relationship between SCLE and nivolumab is suggested by (i) the occurrence of SCLE after at least two cycles, (ii) the regression of lesions following treatment with corticosteroids and hydroxychloroquine, and (iii) the fact that it appeared after remission in our first patient.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30489484</PMID>
<DateCompleted><Year>2019</Year>
<Month>06</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>06</Month>
<Day>14</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-5636</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>29</Volume>
<Issue>2</Issue>
<PubDate><Year>2019</Year>
<Month>04</Month>
</PubDate>
</JournalIssue>
<Title>Melanoma research</Title>
<ISOAbbreviation>Melanoma Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Subacute cutaneous lupus erythematosus induced by nivolumab: two case reports and a literature review.</ArticleTitle>
<Pagination><MedlinePgn>212-215</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/CMR.0000000000000536</ELocationID>
<Abstract><AbstractText>Nivolumab is widely used to treat several late-stage malignancies such as melanoma and non-small-cell lung cancer by inhibiting the interaction between the programmed cell death protein-1 and its ligand. By stimulating an antitumor immune response, it also leads to immune adverse events. Here. we report two cases of subacute cutaneous lupus erythematosus (SCLE) induced by nivolumab. Case 1: a 72-year-old woman with a stage IV melanoma. Two months after nivolumab discontinuation because of autoimmune hepatitis, the patient was in complete remission and pruritic nummular erythematous plaques appeared on the back and arms. Case 2: a 43-year-old man put under nivolumab for a metastatic non-small-cell lung cancer. After two cycles, an annular erythematous eruption appeared on the hands, arms, and chest. The hypothesis of SCLE was confirmed by biopsies showing lymphoid perivascular inflammatory infiltrates, with scarce C3 deposits along the basal layer of the epidermis in patient 2. Both patients tested positive for antinuclear antibodies and anti-SSA antibodies. Lesions were regressive under topical corticosteroids and hydroxychloroquine for the first patient and oral prednisone for the second patient. No systemic involvement was observed. The occurrence of SCLE 2 months after nivolumab discontinuation is evidence that the drug effect is prolonged because of the maintenance of programmed cell death protein-1 reception saturation for months. A causal relationship between SCLE and nivolumab is suggested by (i) the occurrence of SCLE after at least two cycles, (ii) the regression of lesions following treatment with corticosteroids and hydroxychloroquine, and (iii) the fact that it appeared after remission in our first patient.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zitouni</LastName>
<ForeName>Nesrine B</ForeName>
<Initials>NB</Initials>
<AffiliationInfo><Affiliation>Departments of Dermatology.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Arnault</LastName>
<ForeName>Jean-Philippe</ForeName>
<Initials>JP</Initials>
<AffiliationInfo><Affiliation>Departments of Dermatology.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Dadban</LastName>
<ForeName>Ali</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Departments of Dermatology.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Attencourt</LastName>
<ForeName>Christophe</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Pathology, Amiens University Hospital, Amiens, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lok</LastName>
<ForeName>Catherine C</ForeName>
<Initials>CC</Initials>
<AffiliationInfo><Affiliation>Departments of Dermatology.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chaby</LastName>
<ForeName>Guillaume</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Departments of Dermatology.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Melanoma Res</MedlineTA>
<NlmUniqueID>9109623</NlmUniqueID>
<ISSNLinking>0960-8931</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>31YO63LBSN</RegistryNumber>
<NameOfSubstance UI="D000077594">Nivolumab</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008178" MajorTopicYN="N">Lupus Erythematosus, Cutaneous</DescriptorName>
<QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000077594" MajorTopicYN="N">Nivolumab</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year>
<Month>11</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2019</Year>
<Month>6</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2018</Year>
<Month>11</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">30489484</ArticleId>
<ArticleId IdType="doi">10.1097/CMR.0000000000000536</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000074 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000074 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:30489484 |texte= Subacute cutaneous lupus erythematosus induced by nivolumab: two case reports and a literature review. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:30489484" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a ChloroquineV1
This area was generated with Dilib version V0.6.33. |